Through the activation of polar metabolites from bacterial and mammalian cells, MR1T, including MAIT and diverse MR1T cells, could potentially serve as the foundation for novel cancer vaccines or cell therapies using tumor-derived or synthetic MR1 ligands to drive antitumor responses. This evidence concerns the gene MR1 and neoplasm.